Peptides for Neuropathy & Nerve Health
Last updated: 2026-03-24
Neuropathy — damage or dysfunction of peripheral nerves — affects an estimated 2-3% of the general population, with prevalence rising sharply in specific populations: up to 50% of people with diabetes develop diabetic neuropathy, and chemotherapy-induced peripheral neuropathy (CIPN) affects 30-70% of patients receiving neurotoxic chemotherapy regimens. In the United Kingdom, neuropathic pain accounts for a significant proportion of chronic pain consultations and is associated with substantial impairment in quality of life, sleep, and mental health.
The clinical presentations of neuropathy are diverse: distal symmetric polyneuropathy (the classic "glove and stocking" pattern of diabetic neuropathy), small-fibre neuropathy (burning pain with normal nerve conduction studies), autonomic neuropathy, mononeuropathies, and inflammatory demyelinating neuropathies. Current treatment options are largely symptomatic — managing neuropathic pain with medications such as amitriptyline, duloxetine, gabapentin, and pregabalin — rather than addressing the underlying nerve damage. Disease-modifying treatments that promote nerve repair or prevent further nerve degeneration represent a major unmet clinical need.
Peptide research in the neuropathy space has identified several compounds with neuroprotective and neuroregenerative potential. BPC-157 has demonstrated neuroprotective effects in multiple animal models. ARA-290, an erythropoietin-derived peptide, has reached clinical trials specifically for small-fibre neuropathy with encouraging results. Semax promotes BDNF expression and has neuroprotective applications in Russian clinical practice. PACAP (pituitary adenylate cyclase-activating polypeptide) is an endogenous neuropeptide with potent neuroprotective properties.
The evidence base varies considerably between these compounds — from ARA-290's clinical trial data to BPC-157's preclinical observations. This guide presents each compound's evidence level honestly.
Important Disclaimer: Neuropathy has many causes and requires proper medical investigation — diabetes, B12 deficiency, alcohol use, autoimmune conditions, and malignancy must be identified and addressed. No peptides discussed here are approved for treating neuropathy in the UK. This page is for educational purposes only. Consult a neurologist for appropriate assessment and management.
What this guide is — and what to do first
Peptide research for this condition is interesting, but it is not the first thing to consider. The blocks below cover standard UK care, when to see your GP, what licensed treatments exist, and how the peptide evidence actually stacks up.
Standard care first
Neuropathy management requires identifying the cause. Diabetes: optimise glycaemic control (HbA1c). B12 deficiency: replacement. Thyroid disease: optimise. Alcohol: cessation. Chemotherapy-induced: oncology pathway. Idiopathic / chronic: NICE NG193 (neuropathic pain) — first-line amitriptyline, duloxetine, gabapentin, or pregabalin; tramadol second-line; topical capsaicin / lidocaine for localised pain. Physiotherapy for balance / falls prevention. Foot care for diabetic neuropathy to prevent ulceration. Specialist neurology referral for atypical or progressive presentations.
When to speak to your GP
See your GP for new or worsening numbness, tingling, burning pain, weakness, or balance problems. Same-week / urgent assessment for: sudden onset (possible stroke), ascending weakness (possible Guillain-Barré — emergency), associated bowel / bladder dysfunction (possible cauda equina), facial weakness, or symmetric foot ulceration in diabetes. Annual diabetic foot check is mandatory. Do not start any peptide for 'nerve regeneration' from an unregulated source — none have human trial evidence for neuropathy.
UK-approved treatments for this condition
Cause-directed treatment (glycaemic optimisation, B12 replacement, alcohol cessation, etc.). Neuropathic pain pharmacotherapy per NICE NG193: amitriptyline / duloxetine / gabapentin / pregabalin first-line; tramadol second-line. Topical agents: capsaicin cream, lidocaine patches for localised pain. Specialist pain-clinic referral for refractory cases (TENS, spinal cord stimulation in selected cases). Physiotherapy for balance / strengthening. Diabetic foot service for ulcer prevention. No peptide is MHRA-licensed for neuropathy.
What the peptide evidence actually says
| Peptide | Human evidence | UK status | Honest verdict |
|---|---|---|---|
| BPC-157 | None for neuropathy | Unlicensed | Preclinical neuroprotection signal; no human neuropathy trial. |
| LL-37 | None for neuropathy | Unlicensed | Antimicrobial peptide; no neurological-recovery evidence. |
| Cerebrolysin | Some trial activity in stroke / diabetic neuropathy in licensed jurisdictions | Not MHRA-licensed | Mixed-source clinical data; not part of UK NHS pathways. |
| ARA-290 | Some early trials in painful neuropathy | Unlicensed in UK | Investigational; not yet a clinical option. |
How Peptides May Help
Peptides may influence neuropathy and nerve health through several mechanisms:
1. Direct Neuroprotection Several peptides have demonstrated the ability to protect neurones from damage caused by metabolic stress, inflammation, and toxicity. BPC-157 has shown neuroprotective effects in animal models of various neurotoxic injuries, including protection against peripheral nerve damage, central nervous system injury, and neurotoxin-induced neuronal death. The mechanisms include modulation of neurotrophic factor expression, reduction of oxidative stress, and anti-inflammatory effects at the neuronal level. ARA-290 activates the innate repair receptor (a heterodimer of the erythropoietin receptor and beta-common receptor) expressed on nerve fibres, directly promoting neuronal survival and repair.
2. Nerve Fibre Regeneration and Repair Small-fibre neuropathy — characterised by damage to C-fibres and A-delta fibres — is increasingly recognised as a distinct clinical entity. ARA-290 has demonstrated the ability to promote small nerve fibre regeneration in clinical trials, with measurable increases in intraepidermal nerve fibre density (IENFD) — the gold-standard histological measure of small-fibre integrity. This represents genuine neuroregenerative potential, not merely symptomatic relief. Semax, through its BDNF-enhancing effects, may support neuroplasticity and nerve repair processes.
3. Neuroinflammation Reduction Neuroinflammation is a key driver of neuropathy progression in many aetiologies — diabetic neuropathy, CIPN, and autoimmune neuropathies all involve inflammatory damage to nerve fibres and their supporting Schwann cells. BPC-157 modulates inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and has demonstrated anti-inflammatory effects in neurological models. PACAP has potent anti-neuroinflammatory properties, reducing microglial activation and pro-inflammatory mediator release. Selank, through its immunomodulatory properties (as a tuftsin analogue), may modulate neuroinflammatory processes.
4. Neurotrophic Factor Enhancement Neurotrophic factors — BDNF, NGF (nerve growth factor), and GDNF (glial cell-derived neurotrophic factor) — are critical for neuronal survival, axonal growth, and nerve repair. Their depletion contributes to neuropathy progression. Semax significantly upregulates BDNF expression, potentially supporting nerve repair and neuroplasticity. BPC-157 has demonstrated effects on multiple growth factors relevant to nerve healing. PACAP activates the PAC1 receptor, triggering neurotrophic signalling cascades that promote neuronal survival and differentiation.
5. Vascular Support for Nerve Health Peripheral nerves depend on an adequate blood supply (vasa nervorum) for oxygen and nutrient delivery. Microvascular dysfunction — prominent in diabetic neuropathy — compromises nerve health through ischaemic damage. BPC-157 promotes angiogenesis and has demonstrated protective effects on blood vessel integrity. Improved microvascular function may enhance nutrient delivery to damaged nerves, supporting the regenerative environment necessary for nerve repair.
Researched Peptides
BPC-157
Neuroprotective peptide with demonstrated effects across multiple nerve injury models
Preclinical studies demonstrate neuroprotective effects including protection against peripheral nerve injury, neurotoxin-induced damage, and traumatic brain injury. Mechanisms include growth factor upregulation, anti-inflammatory activity, and angiogenesis promotion supporting nerve blood supply. Has shown recovery of function in sciatic nerve injury models. All evidence is preclinical; no human neuropathy trials exist.
ARA-290
Erythropoietin-derived peptide with clinical trial data for small-fibre neuropathy
An 11-amino-acid peptide derived from the erythropoietin molecule that activates the innate repair receptor without the haematopoietic (blood cell-stimulating) effects of erythropoietin itself. Clinical trials in sarcoidosis-associated small-fibre neuropathy demonstrated significant improvements in neuropathic pain, corneal nerve fibre density (a surrogate for small-fibre integrity), and patient-reported outcomes. Represents the most clinically advanced peptide for neuropathy. Also studied in diabetic neuropathy.
Semax
BDNF-enhancing peptide with neuroprotective applications in Russian clinical practice
A synthetic ACTH(4-10) analogue approved in Russia for cognitive disorders and stroke recovery. Significantly upregulates BDNF — a critical neurotrophic factor for neuronal survival and nerve repair. Has demonstrated neuroprotective effects in stroke, traumatic brain injury, and cognitive decline models. Its neurotrophic enhancement may support peripheral nerve regeneration, though this application has not been specifically studied. Not approved outside Russia.
PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide)
Endogenous neuropeptide with potent neuroprotective and neuroregenerative properties
A 38-amino-acid neuropeptide widely distributed in the nervous system with potent neuroprotective effects. Activates PAC1 receptors to trigger neurotrophic signalling cascades. Demonstrated protection against nerve injury, ischaemia, and neuroinflammation in preclinical models. Promotes Schwann cell survival and myelination — critical for peripheral nerve repair. Practical application is limited by rapid degradation and potential side effects (vasodilation, migraine triggering).
Selank
Immunomodulatory peptide with potential neuroinflammatory modulation in neuropathy
As a tuftsin analogue, Selank has immunomodulatory properties that may be relevant to neuroinflammation-driven neuropathies. Its anxiolytic effects (GABA modulation) may help manage the psychological burden of chronic neuropathic pain. Approved in Russia for anxiety and neurasthenic conditions. Its specific application to neuropathy is theoretical, based on its combined immunomodulatory and anxiolytic properties.
Peptide Comparisons
ARA-290 vs BPC-157 for Neuropathy:
These two peptides represent different levels of clinical evidence for neuropathy:
- ARA-290 has the strongest evidence — actual clinical trial data in small-fibre neuropathy demonstrating pain reduction and nerve fibre regeneration. Its mechanism (innate repair receptor activation) is well-characterised and specific to tissue repair - BPC-157 has extensive preclinical evidence across multiple nerve injury models but no human neuropathy trials. Its mechanisms are broader (multi-pathway) and less specifically characterised than ARA-290's - ARA-290 is the more scientifically validated candidate for neuropathy specifically, whilst BPC-157 has a broader evidence base across multiple tissue types - Neither is approved for neuropathy treatment in the UK
For those interested in neuroprotective peptides more broadly, see our Peptides for Cognitive Enhancement guide
Safety Considerations
Important Safety Considerations for Neuropathy Peptides:
Diagnostic Importance: - Neuropathy has many treatable causes: diabetes (optimise glycaemic control), B12 deficiency (supplementation), alcohol (cessation), autoimmune conditions (immunotherapy), and compression neuropathies (surgical decompression) - Identifying and treating the underlying cause is always the priority - New-onset neuropathy requires neurological assessment — it can be a presenting feature of serious conditions including malignancy, vasculitis, and amyloidosis - Self-treating neuropathy with peptides without proper investigation risks missing reversible or dangerous causes
Evidence-Based Neuropathy Treatment: - NICE guideline CG173 (Neuropathic pain) recommends: amitriptyline, duloxetine, gabapentin, or pregabalin as first-line pharmacological options - Diabetic neuropathy management: optimise glycaemic control (HbA1c target), blood pressure, and lipids - CIPN: dose modification of causative chemotherapy where possible - Specialist assessment by a neurologist is recommended for atypical or progressive neuropathy
Peptide-Specific Risks: - ARA-290 has the most clinical safety data among neuropathy-relevant peptides — generally well-tolerated in trials with mild injection site reactions. However, it is not approved for clinical use - BPC-157 lacks human clinical data for neuropathy — safety is extrapolated from animal studies - PACAP administration can trigger migraine and significant vasodilation — problematic for clinical use - Semax and Selank are only approved in Russia — quality of research-grade products internationally cannot be guaranteed
Diabetic Neuropathy Specific: - Diabetic patients considering any peptide should be aware of potential glucose-altering effects (GH secretagogues may impair insulin sensitivity) - Neuropathy progression is most effectively slowed by glycaemic optimisation — this should be the primary focus - Peripheral neuropathy impairs sensation — injection site infections may go undetected in affected areas
General Considerations: - Neuropathic pain is a chronic condition — managing expectations about any intervention is important - Multimodal approaches (pharmacological, physiotherapy, psychological support) typically produce the best outcomes - Peptides are prohibited by WADA in competitive sport
Frequently Asked Questions
Conclusion
Neuropathy represents one of the more promising areas of peptide research, driven by ARA-290's clinical trial data demonstrating genuine nerve fibre regeneration — a therapeutic effect that no currently approved neuropathy treatment achieves. The broader peptide landscape, including BPC-157's neuroprotective effects, Semax's BDNF enhancement, and PACAP's neurotrophic signalling, provides a rich mechanistic framework for addressing the unmet need for disease-modifying neuropathy treatments.
The distinction between symptomatic treatment (managing neuropathic pain) and disease modification (promoting nerve repair, halting progression) is critical. Current treatments are primarily symptomatic, and patients continue to experience progressive nerve damage despite pain management. Peptides that address the underlying nerve damage — particularly ARA-290's demonstrated neuroregenerative capacity — represent a fundamentally different therapeutic approach.
However, the evidence remains at varying stages of development, and no peptides are currently available as neuropathy treatments. Proper neurological assessment, identification of treatable causes, and optimisation of evidence-based management (glycaemic control, neuropathic pain medications, physiotherapy) remain the priority.
*This page is for educational and informational purposes only. Neuropathy requires proper medical investigation to identify treatable causes. No peptides are approved for neuropathy treatment. Consult a neurologist for appropriate assessment and management.*
Medical Disclaimer
The information provided on this page is for educational and research purposes only. The peptides discussed are not approved medications for the conditions described. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.
Related Categories
Explore Other Guides
Peptides for Tendon Injuries & Repair
Tendon injuries—whether from sports, repetitive strain, or age-related degeneration—represent some of the most challengi...
Peptides for Fat Loss & Weight Management
The search for effective weight management solutions has led researchers to investigate various peptides that may influe...
Peptides for Muscle Growth & Recovery
The pursuit of enhanced muscle growth, improved recovery, and optimised body composition has driven significant interest...
Peptides for Anti-Ageing & Longevity
The science of ageing has advanced dramatically, moving from inevitable decline to a potentially modifiable process. Pep...
Peptides for Cognitive Enhancement & Brain Health
Cognitive enhancement—improving memory, focus, mental clarity, and brain health—has become a major area of interest in p...
Peptides for Immune Support & Function
The immune system's complexity and critical role in health has made it a major focus of peptide research. From thymic pe...
Peptides for Sexual Health & Function
Sexual health encompasses physical function, desire, satisfaction, and psychological wellbeing—all influenced by complex...
Peptides for Joint Health & Cartilage Repair
Joint health issues—including osteoarthritis, cartilage degeneration, and chronic joint pain—affect millions of people w...
Peptides for Sleep Optimization & Sleep Quality
Sleep is fundamental to health, affecting everything from cognitive function and immune defence to metabolic regulation ...
Peptides for Blood Sugar Management & Glycaemic Control
Blood sugar dysregulation affects hundreds of millions of people globally. Type 2 diabetes alone impacts over 530 millio...
Peptides for Anxiety & Stress Reduction
Anxiety and chronic stress affect millions of people worldwide and represent a growing area of unmet clinical need. Whil...
Peptides for Athletic Performance & Recovery
The intersection of peptide science and sports performance has become one of the most actively researched — and debated ...
Peptides for Heart Health & Cardiovascular Support
Cardiovascular disease remains the leading cause of death worldwide, accounting for approximately 17.9 million deaths an...
Peptides for Liver Health & Detoxification
The liver is the body's primary metabolic and detoxification organ, responsible for over 500 essential functions includi...
Peptides for Autoimmune Conditions & Immune Modulation
Autoimmune diseases — conditions in which the immune system mistakenly attacks the body's own tissues — affect approxima...
Peptides for Post-Surgery Recovery & Wound Healing
Post-surgical recovery is a complex physiological process involving haemostasis, inflammation, proliferation, and remode...
Peptides for Skin Pigmentation & Tanning
Skin pigmentation is primarily determined by the production and distribution of melanin — a family of pigments synthesis...
Peptides for Fertility & Reproductive Health
Fertility and reproductive health are regulated by an intricate hormonal network centred on the hypothalamic-pituitary-g...
Peptides for Weight Loss
Weight loss has become one of the most significant public health priorities in the United Kingdom. According to NHS Engl...
Peptides for Diabetes & Blood Sugar Control
Type 2 diabetes is one of the most significant health challenges facing the United Kingdom. Diabetes UK estimates that a...
Peptides for Bodybuilding & Muscle Gain
Bodybuilding and strength sports have long driven interest in compounds that may enhance muscle growth, accelerate recov...
Peptides for Knee Pain & Joint Support
Knee pain is one of the most prevalent musculoskeletal complaints worldwide, affecting an estimated 25% of adults and ac...
Peptides for Back Pain & Spinal Health
Back pain is the leading cause of disability worldwide and one of the most common reasons for GP consultations in the Un...
Peptides for IBS & Digestive Disorders
Irritable bowel syndrome (IBS) affects an estimated 10-15% of the UK population and is the most common functional gastro...
Peptides for Depression & Mood Support
Depression is one of the most prevalent mental health conditions globally, affecting an estimated 5% of the adult popula...
Peptides for PCOS (Polycystic Ovary Syndrome)
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age, with an esti...
Peptides for Chronic Fatigue & CFS/ME
Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME) or ME/CFS, is a complex, debilitating condi...
Peptides for Thyroid Health & Function
Thyroid disorders are among the most common endocrine conditions in the United Kingdom, affecting an estimated 2-5% of t...
Peptides for Respiratory & Lung Health
Respiratory disease is the third leading cause of death in the United Kingdom, with chronic obstructive pulmonary diseas...
Peptides for Long COVID & Post-Viral Syndrome
Long COVID — formally known as post-COVID-19 syndrome — affects an estimated 1.9 million people in the UK (ONS, 2024). D...
Peptides for Fibromyalgia & Chronic Pain
Fibromyalgia is a chronic condition characterised by widespread musculoskeletal pain, fatigue, sleep disturbance, and co...
Peptides for Lyme Disease & Post-Treatment Syndrome
Lyme disease, caused by the spirochaete bacterium *Borrelia burgdorferi* (and related species *B. garinii* and *B. afzel...
Peptides for Erectile Dysfunction & Sexual Performance
Erectile dysfunction (ED) affects an estimated 4.3 million men in the UK, with prevalence increasing significantly after...
Peptides for Infertility: Male & Female Fertility Research
Infertility affects approximately 1 in 7 couples in the UK, with roughly equal contributions from male and female factor...
Peptides for Osteoarthritis & Joint Health
Osteoarthritis (OA) affects over 10 million people in the UK and is the most common form of arthritis, characterised by ...
Peptides for Menopause: Hot Flashes, Bone Loss, Skin & Mood
Menopause affects every woman, typically occurring between ages 45-55 in the UK, with an average age of 51. The decline ...
Peptides for Migraine Prevention
Migraine affects approximately 10 million people in the UK and is the third most common disease globally. While recent C...
Peptides for Neuropathic Pain & Nerve Damage
Neuropathic pain — caused by damage or dysfunction of the nervous system itself — affects approximately 7-8% of the UK p...
Peptides for Disc Degeneration & Back Pain
Intervertebral disc degeneration is the most common cause of chronic lower back pain, affecting an estimated 80% of adul...
Peptides for Frozen Shoulder Recovery
Frozen shoulder (adhesive capsulitis) affects 2-5% of the general population and up to 20% of people with diabetes. It c...
Peptides for Bone Density & Osteoporosis Prevention
Osteoporosis affects approximately 3.5 million people in the UK, causing over 500,000 fragility fractures annually. The ...
Peptides for Cardiovascular Health & Heart Protection
Cardiovascular disease (CVD) remains the UK's leading cause of death, accounting for approximately 160,000 deaths annual...
Peptides for Thyroid Function & Support
Thyroid disorders affect approximately 2-5% of the UK population, with hypothyroidism being far more common than hyperth...
Musculoskeletal Recovery — peptide research hub
Peptide research that touches the musculoskeletal system spans tendon and ligament repair, joint inflammation, cartilage...
Metabolic and Weight — peptide research hub
The metabolic-and-weight space is the most heavily-licensed corner of peptide medicine in the UK — semaglutide (Wegovy /...
Neuro and Mood — peptide research hub
Neuropeptide research is dominated by compounds developed in Russia and Eastern Europe with decades of regional clinical...
Immune and Inflammation — peptide research hub
Immune-modulating and anti-inflammatory peptides are an active research area with thin human-trial data for the conditio...
Skin and Aesthetics — peptide research hub
Cosmetic peptide use splits into two very different categories: topical peptides (GHK-Cu, Matrixyl, Argireline, SNAP-8) ...
Hormonal and Reproductive — peptide research hub
Hormonal and reproductive-health peptides span fertility hormones (gonadorelin, GnRH analogues), menopause-related resea...
Peptides for Hair Growth & Follicle Health
Hair loss affects millions of people worldwide, with androgenetic alopecia (pattern baldness), telogen effluvium, and al...
Peptides for Skin Health & Anti-Ageing
Peptides have revolutionised modern skincare, offering science-backed approaches to anti-ageing, wound healing, and skin...
Peptides for Gut Health & Digestive Repair
Gastrointestinal health is fundamental to overall wellbeing, influencing everything from nutrient absorption and immune ...
Peptides for Wrinkle Reduction & Skin Rejuvenation
Cosmetic peptides have revolutionised the skincare industry, offering targeted mechanisms for addressing different types...
Peptides for Skin Firmness & Collagen Restoration
Skin firmness depends fundamentally on the dermal extracellular matrix—a dense network of collagen, elastin, and glycosa...
Peptides for Wound Healing & Tissue Repair
Wound healing is a complex, multi-phase biological process involving inflammation, proliferation, and remodelling. Chron...
Peptides for Inflammation & Immune Modulation
Chronic inflammation underlies many of the most prevalent health conditions—from autoimmune disorders and cardiovascular...
Peptides for Bone Health & Fracture Recovery
Bone health is a critical concern across the lifespan—from fracture healing in athletes and trauma patients to osteoporo...
Peptides for Anxiety & Stress Management
Anxiety disorders are among the most prevalent mental health conditions globally, affecting approximately 284 million pe...
Peptides for Energy & Metabolic Optimisation
Energy metabolism—the complex system by which cells convert nutrients into usable energy—underlies virtually every aspec...